CD69 通过免疫细胞浸润和地西他滨治疗反应预测急性髓性白血病的预后。

IF 1.5 4区 医学 Q4 ONCOLOGY
Translational cancer research Pub Date : 2025-02-28 Epub Date: 2025-02-26 DOI:10.21037/tcr-24-1550
Jie Zhou, Hao Wu, Bing Li, Lixin Lv, Shunli Zhu, Aibin Liang, Jianfei Fu
{"title":"CD69 通过免疫细胞浸润和地西他滨治疗反应预测急性髓性白血病的预后。","authors":"Jie Zhou, Hao Wu, Bing Li, Lixin Lv, Shunli Zhu, Aibin Liang, Jianfei Fu","doi":"10.21037/tcr-24-1550","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Acute myeloid leukemia (AML) is a heterogeneous myeloid neoplasm. Recent studies have focused on unraveling the complexities of the tumor microenvironment (TME) and its impact on AML, with a specific emphasis on CD69, a potential TME regulator. However, the precise relationship between CD69 and AML is yet to be fully elucidated. This study aimed to analyze the heterogeneous gene expression landscape of AML patients using public databases, and to elucidate the relationship between CD69 expression and the pathophysiology of AML.</p><p><strong>Methods: </strong>Three gene datasets from Gene Expression Omnibus (GEO), ribonucleic acid (RNA) sequence data from The Cancer Genome Atlas (TCGA) and Therapeutically Applicable Research to Generate Effective Treatments (TARGET), and tumor cell lines data from Cancer Cell Line Encyclopedia (CCLE) were used. The Cox proportional hazards regression model was employed to assess the impact of differentially expressed genes on the overall survival (OS) rate of AML. Spearman's rank correlation coefficient analysis was conducted to determine the relationship between CD69 and immune cell infiltration in AML patients. Western blot analysis was utilized to verify CD69 expression in AML cell lines.</p><p><strong>Results: </strong>(I) Gene expression: 13 differentially expressed genes were identified in AML. (II) Impact on survival: CD69 expression was inversely related to OS of AML patients, with lower CD69 levels correlating with improved survival outcomes. (III) Independent risk factors: CD69, ITGB7, SCD and age were identified as independent risk factors in AML. (IV) Immune cell infiltration: a higher expression of CD69 was associated with reduced infiltration of CD8+ T cells and macrophages in AML. (V) Effect of decitabine (DA) treatment: AML patients treated with DA exhibited decreased CD69 expression.</p><p><strong>Conclusions: </strong>The study established a correlation between the expression of ITGB7, SCD, CD69 and the OS in AML patients. SCD, ITGB7 and age were identified as key prognostic factors. The multifaceted role of CD69 in AML, encompassing its association with prognosis, immune cell infiltration, and response to chemotherapy, underscores its potential as a key player in the complex landscape of AML pathogenesis and treatment response.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 2","pages":"865-880"},"PeriodicalIF":1.5000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912086/pdf/","citationCount":"0","resultStr":"{\"title\":\"CD69 predicts prognosis through immune cell infiltration and decitabine treatment response in acute myeloid leukemia.\",\"authors\":\"Jie Zhou, Hao Wu, Bing Li, Lixin Lv, Shunli Zhu, Aibin Liang, Jianfei Fu\",\"doi\":\"10.21037/tcr-24-1550\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Acute myeloid leukemia (AML) is a heterogeneous myeloid neoplasm. Recent studies have focused on unraveling the complexities of the tumor microenvironment (TME) and its impact on AML, with a specific emphasis on CD69, a potential TME regulator. However, the precise relationship between CD69 and AML is yet to be fully elucidated. This study aimed to analyze the heterogeneous gene expression landscape of AML patients using public databases, and to elucidate the relationship between CD69 expression and the pathophysiology of AML.</p><p><strong>Methods: </strong>Three gene datasets from Gene Expression Omnibus (GEO), ribonucleic acid (RNA) sequence data from The Cancer Genome Atlas (TCGA) and Therapeutically Applicable Research to Generate Effective Treatments (TARGET), and tumor cell lines data from Cancer Cell Line Encyclopedia (CCLE) were used. The Cox proportional hazards regression model was employed to assess the impact of differentially expressed genes on the overall survival (OS) rate of AML. Spearman's rank correlation coefficient analysis was conducted to determine the relationship between CD69 and immune cell infiltration in AML patients. Western blot analysis was utilized to verify CD69 expression in AML cell lines.</p><p><strong>Results: </strong>(I) Gene expression: 13 differentially expressed genes were identified in AML. (II) Impact on survival: CD69 expression was inversely related to OS of AML patients, with lower CD69 levels correlating with improved survival outcomes. (III) Independent risk factors: CD69, ITGB7, SCD and age were identified as independent risk factors in AML. (IV) Immune cell infiltration: a higher expression of CD69 was associated with reduced infiltration of CD8+ T cells and macrophages in AML. (V) Effect of decitabine (DA) treatment: AML patients treated with DA exhibited decreased CD69 expression.</p><p><strong>Conclusions: </strong>The study established a correlation between the expression of ITGB7, SCD, CD69 and the OS in AML patients. SCD, ITGB7 and age were identified as key prognostic factors. The multifaceted role of CD69 in AML, encompassing its association with prognosis, immune cell infiltration, and response to chemotherapy, underscores its potential as a key player in the complex landscape of AML pathogenesis and treatment response.</p>\",\"PeriodicalId\":23216,\"journal\":{\"name\":\"Translational cancer research\",\"volume\":\"14 2\",\"pages\":\"865-880\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-02-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912086/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/tcr-24-1550\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-1550","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/26 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
CD69 predicts prognosis through immune cell infiltration and decitabine treatment response in acute myeloid leukemia.

Background: Acute myeloid leukemia (AML) is a heterogeneous myeloid neoplasm. Recent studies have focused on unraveling the complexities of the tumor microenvironment (TME) and its impact on AML, with a specific emphasis on CD69, a potential TME regulator. However, the precise relationship between CD69 and AML is yet to be fully elucidated. This study aimed to analyze the heterogeneous gene expression landscape of AML patients using public databases, and to elucidate the relationship between CD69 expression and the pathophysiology of AML.

Methods: Three gene datasets from Gene Expression Omnibus (GEO), ribonucleic acid (RNA) sequence data from The Cancer Genome Atlas (TCGA) and Therapeutically Applicable Research to Generate Effective Treatments (TARGET), and tumor cell lines data from Cancer Cell Line Encyclopedia (CCLE) were used. The Cox proportional hazards regression model was employed to assess the impact of differentially expressed genes on the overall survival (OS) rate of AML. Spearman's rank correlation coefficient analysis was conducted to determine the relationship between CD69 and immune cell infiltration in AML patients. Western blot analysis was utilized to verify CD69 expression in AML cell lines.

Results: (I) Gene expression: 13 differentially expressed genes were identified in AML. (II) Impact on survival: CD69 expression was inversely related to OS of AML patients, with lower CD69 levels correlating with improved survival outcomes. (III) Independent risk factors: CD69, ITGB7, SCD and age were identified as independent risk factors in AML. (IV) Immune cell infiltration: a higher expression of CD69 was associated with reduced infiltration of CD8+ T cells and macrophages in AML. (V) Effect of decitabine (DA) treatment: AML patients treated with DA exhibited decreased CD69 expression.

Conclusions: The study established a correlation between the expression of ITGB7, SCD, CD69 and the OS in AML patients. SCD, ITGB7 and age were identified as key prognostic factors. The multifaceted role of CD69 in AML, encompassing its association with prognosis, immune cell infiltration, and response to chemotherapy, underscores its potential as a key player in the complex landscape of AML pathogenesis and treatment response.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.10
自引率
0.00%
发文量
252
期刊介绍: Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信